Skip to main content

Core Industry Metrics

As part of our mission to be the industry’s go-to source for market data, we provide and update this repository of core pharmaceutical industry metrics free to interested parties. To download the raw data MS Excel sets, use the links below.

CRO Core Metrics   |   CMO Core Metrics   |   Other Core Industry Metrics

Excel sets last updated: July 2023 with data from Q1, 2023

*IQVIA (Quintiles) total gross revenue has been adjusted to the proportion related to R&D solutions. =0.647
PRA and ICON merged in July, 2021 – data will be combined going forward (Q3, 2021)

*Celltrion removed because financials include innovator drugs and CDMO services.

*Companies included: Viatris, Teva, Sun Pharmaceutical, Aurobindo, Lupin
**Innovator companies and companies with medical device offerings omitted from above rankings.

*Companies included: J&J, Pfizer, Roche, Novartis, Merck & Co., GlaxoSmithKline, Sanofi, AbbVie, Takeda, Shanghai Pharmaceuticals

Top 20 Drug Sales

Source: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales

No.
Drug Name
Active Ingredient
Approval Date
FDA-approved use on approval date*
1
Leqembi
lecanemab-irmb
1/6/2023
To treat Alzheimer’s disease
2
Brenzavvy
bexagliflozin
1/20/2023
To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
3
Jaypirca
pirtobrutinib
1/27/2023
To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
4
Orserdu
elacestrant
1/27/2023
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
5
Jesduvroq
daprodustat
2/1/2023
To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
6
Lamzede
velmanase alfa-tycv
2/16/2023
To treat non-central nervous system manifestations of alpha-mannosidosis
7
Filspari
sparsentan
2/17/2023
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
8
Skyclarys
omaveloxolone
2/28/2023
To treat Friedrich’s ataxia
9
Zavzpret
zavegepant
3/9/2023
To treat migraine
10
Daybue
trofinetide
3/10/2023
To treat Rett syndrome
11
Zynyz
retifanlimab-dlwr
3/22/2023
To treat metastatic or recurrent locally advanced Merkel cell carcinoma
12
Rezzayo
rezafungin
3/22/2023
To treat candidemia and invasive candidiasis
13
Joenja
leniolisib
3/24/2023
To treat activated phosphoinositide 3-kinase delta syndrome
14
Qalsody
tofersen
4/25/2023
To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation
15
Elfabrio
pegunigalsidase alfa-iwxj
5/9/2023
To treat confirmed Fabry disease
16
Veozah
fezolinetant
5/12/2023
To treat moderate to severe hot flashes caused by menopause
17
Miebo
perfluorhexyloctane
5/18/2023
To treat signs and symptoms of dry eye disease
18
Epkinly
epcoritamab-bysp
5/19/2023
To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
19
Xacduro
sulbactam, durlobactam
5/23/2023
To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
20
Paxlovid
nirmatrelvir, ritonavir
5/25/2023
To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
21
Posluma
flotufolastat F 18
5/25/2023
To use with positron emission tomography imaging in certain patients with prostate cancer
22
Inpefa
sotagliflozin
5/26/2023
​To treat heart failure
23
Columvi
glofitamab-gxbm
6/15/2023
​To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
24
Litfulo
ritlecitinib
6/24/2023
​To treat severely patchy hair loss

Core Industry Metrics Updates

Sign up to receive a notification when we update our Core Pharmaceutical Industry Metrics.